Hepatocyte liver-assist systems - A clinical update

Mayo Clinic Proceedings

Volumn 73, Issue 8, 1998, Pages 765-771

  Nyberg, Scott L ^a,b   Misra, Sri Prakash ^b  

^a Division of Transplantation   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL ORGAN; DEVICE; HEMOPERFUSION; INNER CELL MASS; LIVER FAILURE; LIVER FUNCTION; LIVER PERFUSION; METABOLIC ACTIVATION; REVIEW; SURVIVAL;

EID: 0031828754     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/73.8.765     Document Type: Review

References (61)

1. Matsumura KM, Guevara GR, Huston H, Hamilton WL, Rikimaru M, Yamasaki G, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987;101:99-103
2. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989;18:85-94
3. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994:18:390-396
4. Gerlach JC. Development of a hybrid liver support system: a review. IntJ Artif Organs 1996;19:645-654
5. Ellis AJ, Hughes RD, Wenden JA, Dünne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451
6. Watanabe FD, Million CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial. Ann Surg 1997;225:484-491
7. Nyberg SL, Shatford RA, Hu WS, Payne WD, Cerra FB. Hepatocyte culture systems for artificial liver support: implications for critical care medicine (bioartificial liver support). Crit Care Med 1992;20:11571168
8. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB. Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg 1993:166:512-521
9. Jauregui HO, Chowdhury NR, Chowdhury JR. Use of mammalian liver cells for artificial liver support. Cell Transplant 1996:5:353-367
10. Mito M, Kusano M. Hepatocyte transplantation in man. Cell Transplant 1993:2:65-74
11. Schumacher IK, Okamoto T, Kim BH, Chowdhury NR, Chowdhury JR, Fox IJ. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology 1996;24:337343
12. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186 1192
13. Hughes RD, Pucknell A, Routley D, Langley PG, Wenden JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994;17:657662
14. Tygstrup N, Larsen FS, Hansen BA. Treatment of acute liver fail u re by high volume plasmapheresis. In: Lee WM, Williams R, editors. Acute Liver Failure. Cambridge (England): Cambridge University Press; 1997. pp 267-277
15. Fox IJ, Langnas AN, Fristoe LW, Shaefer MS, Vogel JE, Antonson DL, et al. Successful application of extracorporeal liver perfusion: a technology whose time has come. Am J Gastmenterol 1993; 88:1876-1881
16. Chari RS, Collins BH, Magee JC, DiMaio JM, Kirk AD, Harland RC, et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med 1994; 331:234-237
17. Ryan CM, Carter EA, Jenkins RL, Sterling LM, Yarmush ML, Malt RA, et al. Isolation and long-term culture of human hepatocytes. Surgery 1993;113:48-54
18. Li AP, Barker G, Beck D, Colburn S, Monsell R, Pellegrin C. Culturing of primary hepatocytes as entrapped aggregates in a packed bed bioreactor: a potential bioartificial liver. In Vitro Cell Dev Biol 1993;29A:249-254
19. Kelly JH, inventor; Baylor College of Medicine, assignee. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). US patent 5,290,684. 1994 Mar 1
20. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994;220:59-67
21. Imaoka S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T, et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 1990;255:13851391
22. Muller TE, Jauregui HO. Response to letter. Artif Organs 1993; 17:44-45
23. Stange J, Mitzner S. Cell sources for bioartificial liver support. Int J Artif Organs 1996:19:14-17
24. Rozga J, LePage E, Morsiani E, Demetriou A. Liver support system development. In: Demetriou AA, editor. Support of the Acutely Failing Liver. Austin (TX): RG Landes; 1993. pp 60-81
25. Sielaff TD, Hu MY, Rao S, Groehler K, Oison D, Mann HJ, et al. A technique for porcine hepatocyte harvest and description of differentiated metabolic functions in static culture. Transplantation 1995:59:1459-1463
26. Gerlach J, Brombacher J, Smith M, Neuhaus P. High yield hepatocyte isolation from pig livers for investigation of hybrid liver support systems: influence of collagenase concentration and body weight. J Surg Res 1996:62:85-89
27. Joly A, Desjardins JF, Fremond B, Desille M, Campion JP, Malledant Y, et al. Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads: a step toward a reliable bioartificial liver. Transplantation 1997;63:795803
28. Neuzil DF, Rozga J, Moscioni AD, Ro MS, Hakim R, Arnaout WS, et al. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surgery 1993:113:340-343
29. Abouna GM, Boehmig HG, Serrou B, Amemiya H, Martineau G. Longterm hepatic support by intermittent multi-species liver perfusions. Lancet 1970;2:391-396
30. Fishman JA. Miniature swine as organ donors for man: strategies for prevention of xenotransplant-associated infections. Xenotransplantation 1994;l:47-57
31. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997:3:282-286
32. Le Tissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus [letter]. Nature 1997:389:681682
33. de Groen PC. Hepatitis E in the United States: a case of "hogfever"? [editorial]. Mayo Clin Proc 1997:72:1197-1198
34. Gerlach JC, Fuchs M, Smith MD, Bornemann R, Encke J, Neuhaus P, et al. Is a clinical application of hybrid liver support systems limited by an initial disorder in cellular amino acid and alpha-keto acid metabolism, rather than by later gradual loss of primary hepatocyte function? Transplantation 1996;62:224-228
35. Nagasue N, Yukaya H, Ogawa Y, Kohno H, Nakamura T. Human liver regeneration after major hepatic resection: a study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg 1987;206:3039
36. Bucher NLR. Regeneration of mammalian liver. Int Rev Cytol 1963; 15:245-300
37. JonesAL. Anatomy of the normal liver. In: Zakim D, Boyer TD, editors. Hepatology: A Textbook of Liver Disease. Voll. 2nd ed. Philadelphia: Saunders; 1990. pp 3-30
38. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani E, Moscioni AD, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 1995;208:111-117
39. Bornemann R, Smith MD, Gerlach JC. Consideration of potential immunological problems in the application of xenogenic hybrid liver support. Int J Artif Organs 1996:19:655-663
40. Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 1965;162:329-345
41. Watts JM, Douglas MC, Dudley HA, Gurr FW, Owen JA. Heterologous liver perfusion in acute hepatic failure. BMJ 1967;2:341-345
42. Baquerizo A, M hoy an A, Shirwan H, Swensson J, Busuttil RW, Demetriou AA, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc 1997;29:964-965
43. Auchincloss H Jr. Cell-mediated xenoresponses: strong or weak? Clin Transplant 1994;8:155-159
44. Peltekian KM, Levy GA. Role of cytokines and immune mechanisms in acute liver failure. In: Lee WM, Williams R, editors. /Acute Liver Failure. Cambridge (England): Cambridge University Press; 1997. pp 67-78
45. Giorgio TD, Moscioni AD, Rozga J, Demetriou AA. Mass transfer in a hollow fiber device used as a bioartificial liver. ASAIO J 1993;39:886892
46. ChangTM. Haemoperfusions over microencapsulated adsorbent in a patient with hepatic coma. Lancet 1972;2:1371-1372
47. Gazzard BG, Weston MJ, Murray-Lyon IM, Flax H, Record CO, Williams R, et al. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974:1:1301-1307
48. Rozga J, Holzman MD, Ro MS, Griffin DW, Neuzil DF, Giorgio T, et al. Development of a hybrid bioartificial liver. Ann Surg 1993:217:502-509
49. Hughes R, Williams R. Clinical experience with charcoal and resin hemoperfusion. Semin Liver Dis 1986;6:164-173
50. Rozga J, Podesta L, LePage E, Huffman A, Morsiani E, Sher L, et al. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993:342:898899
51. Coffman KL, Huffman A, Rosenthal P, Demetriou A, Makowka L. Neurological and psychological sequelae in transplant recipients after bridging with the bioartificial liver. Gen Hosp Psychiatry 1996; 18(Suppl):20S-24S
52. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 1991;43:2771
53. Butterworth RF. Hepatic encephalopathy and brain edema in acute hepatic failure: does glutamate play a role? [editorial]. Hepatology 1997;25:1032-1034
54. Denis J, Delorme ML, Boschat M, Nordlinger B, Opolon P. Respective roles of ammonia, amino acids, and medium-sized molecules in the pathogenesis of experimentally induced acute hepatic encephalopathy. J Neurochem 1983;40:10-19
55. Rozga J, Podesta L, LePage E, Morsiani E, Moscioni AD, H off ma n A, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994;219:538-544
56. Watanabe FD, Demetriou AA. Support of acute liver failure patients with a bioartificial liver. J Clin Apheresis 1996;11:138-142
57. Kelly JH, Koussayer T, He D, Chong MG, Shang TA, Whisennand HH, et al. Assessment of an extracorporeal liver assist device in anhepatic dogs. Artif Organs 1992;16:418-422
58. Sussman NL, Chong MG, Koussayer T, He DE, Shang TA, Whisennand HH, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992:16:60-65
59. Gibbs WW. Deliverance: medicine closes in on an artificial liver device. Sei Am 1993 Dec;269:30-33
60. Knowles BB, Howe CC Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980:209:497-499
61. Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology 1994;20(Suppl):5S10S